Cereda Vittore, D'Andrea Mario Rosario
Asl Roma 4, Hospital S. Paolo Civitavecchia, 00053 Civitavecchia, Italy.
Explor Target Antitumor Ther. 2025 Mar 18;6:1002299. doi: 10.37349/etat.2025.1002299. eCollection 2025.
Pancreatic cancer is a challenging disease with limited treatment options and a high mortality rate. Just few therapy advances have been made in recent years. Tumor microenvironment, immunosuppressive features and mutational status represent important obstacles in the improvement of survival outcomes. Up to now, first-line therapy did achieve a median overall survival of less than 12 months and this discouraging data lead clinicians all over the world to focus their efforts on various fields of investigation: 1) sequential cycling of different systemic therapy in order to overcome mechanisms of resistance; 2) discovery of new predictive bio-markers, in order to target specific patient population; 3) combination treatment, in order to modulate the tumor microenvironment of pancreatic cancer; 4) new modalities of the delivery of drugs in order to pass the physical barrier of desmoplasia and tumor stroma. This review shows future directions of treatment strategies in advanced pancreatic cancer through a deep analysis of these recent macro areas of research.
胰腺癌是一种具有挑战性的疾病，治疗选择有限且死亡率高。近年来治疗进展甚微。肿瘤微环境、免疫抑制特征和突变状态是改善生存结果的重要障碍。到目前为止，一线治疗的中位总生存期不到12个月，这一令人沮丧的数据促使世界各地的临床医生将精力集中在各个研究领域：1）不同全身治疗的序贯循环，以克服耐药机制；2）发现新的预测生物标志物，以针对特定患者群体；3）联合治疗，以调节胰腺癌的肿瘤微环境；4）新的药物递送方式，以突破纤维增生和肿瘤基质的物理屏障。本综述通过对这些近期主要研究领域的深入分析，展示了晚期胰腺癌治疗策略的未来方向。
